Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes-Reference-Cited by-同舟云学术

Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes

Published:2022-12-09 Issue:2 Volume:55 Page:392-398
ISSN:1573-742X
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Hantrakun Nonthakorn^ORCID,Wongcharoen Wanwarang,Thiankhaw Kitti,Norasetthada Lalita,Tantiworawit Adisak,Rattarittamrong Ekarat,Rattanathammethee Thanawat,Hantrakool Sasinee,Piriyakhuntorn Pokpong,Punnachet Teerachat,Niprapan Piangrawee,Chai-Adisaksopha Chatree^ORCID

Funder

Faculty of Medicine, Chiang Mai University

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

https://link.springer.com/content/pdf/10.1007/s11239-022-02747-w.pdf

Reference13 articles.

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al (2009) Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561

2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J 42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612

3. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus Warfarin in the treatment of Acute venous thromboembolism. N Engl J Med 361(24):2342–2352. https://doi.org/10.1056/NEJMoa0906598

4. Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M et al (2013) Model-based dose selection for phase III rivaroxaban study in japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 28(1):59–70. https://doi.org/10.2133/dmpk.DMPK-12-RG-034

5. Hori M, Matsumoto M, Tanahashi N, Momomura S-i, Uchiyama S, Goto S et al (2012) Rivaroxaban vs. Warfarin in japanese patients with Atrial Fibrillation. Circ J 76(9):2104–2111. https://doi.org/10.1253/circj.CJ-12-0454